Merck’s prevailing Vioxx strategy

One method is to hope that the plaintiffs die:

Wall Street now believes Merck’s ultimate Vioxx liability is closer to $5 billion than $25 billion, Lehman Brothers analyst Tony Butler adds. The reasoning – with fewer than 20 lawsuits so far making it to trial, some plaintiffs won’t live long enough to see any money.

Related posts:

1. "What has William McGuire done to advance the cause of medicine?"
2. A jury of "uneducated casino workers" beat the hell out of Merck
3. Merck wins another Vioxx suit
4. Vioxx: The lottery may be running dry
5. Merck sends in the B-team for a physician expert witness
6. Vioxx plaintiff faces a choice
7. How tort reform can stimulate the economy

  Follow on Twitter   Subscribe